WO2016072655A1 - 결명자 유산균 발효물을 유효성분으로 하는 변비 개선, 치료 또는 예방용 조성물 및 그 제조방법 - Google Patents
결명자 유산균 발효물을 유효성분으로 하는 변비 개선, 치료 또는 예방용 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- WO2016072655A1 WO2016072655A1 PCT/KR2015/011359 KR2015011359W WO2016072655A1 WO 2016072655 A1 WO2016072655 A1 WO 2016072655A1 KR 2015011359 W KR2015011359 W KR 2015011359W WO 2016072655 A1 WO2016072655 A1 WO 2016072655A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- lactobacillus
- acid bacteria
- constipation
- extract
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 164
- 241000894006 Bacteria Species 0.000 title claims abstract description 93
- 239000004310 lactic acid Substances 0.000 title claims abstract description 82
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 82
- 206010010774 Constipation Diseases 0.000 title claims abstract description 71
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 230000006872 improvement Effects 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 title claims description 12
- 244000037364 Cinnamomum aromaticum Species 0.000 title abstract description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title abstract description 7
- 239000004615 ingredient Substances 0.000 title abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 37
- 241001468191 Lactobacillus kefiri Species 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims description 91
- 238000000855 fermentation Methods 0.000 claims description 91
- 230000004151 fermentation Effects 0.000 claims description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 76
- 239000000047 product Substances 0.000 claims description 58
- 241000186660 Lactobacillus Species 0.000 claims description 50
- 229940039696 lactobacillus Drugs 0.000 claims description 43
- 239000007864 aqueous solution Substances 0.000 claims description 20
- 230000007812 deficiency Effects 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 235000015872 dietary supplement Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 7
- 241000192001 Pediococcus Species 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 241000194033 Enterococcus Species 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 98
- 230000001965 increasing effect Effects 0.000 abstract description 28
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 abstract description 13
- 229930186851 sennoside Natural products 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 6
- 210000003608 fece Anatomy 0.000 abstract description 6
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000503 bisacodyl Drugs 0.000 abstract 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 abstract 1
- 229960000878 docusate sodium Drugs 0.000 abstract 1
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 abstract 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 42
- 229960001571 loperamide Drugs 0.000 description 42
- 238000007920 subcutaneous administration Methods 0.000 description 23
- 239000013642 negative control Substances 0.000 description 16
- 238000010171 animal model Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 229940099198 dulcolax Drugs 0.000 description 12
- 235000013305 food Nutrition 0.000 description 10
- 229940124513 senna glycoside Drugs 0.000 description 10
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 9
- 241000186605 Lactobacillus paracasei Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 235000012730 carminic acid Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 244000201986 Cassia tora Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- 235000014552 Cassia tora Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 244000277285 Cassia obtusifolia Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000191996 Pediococcus pentosaceus Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 flakes Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000010369 Cascara Substances 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010065420 Coronary artery dilatation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000556215 Frangula purshiana Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000522641 Senna Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229940071704 cascara sagrada Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- JCEGKJFZOJBPOL-UHFFFAOYSA-N ethanol;2-hydroxypropanoic acid Chemical compound CCO.CC(O)C(O)=O JCEGKJFZOJBPOL-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- UTELBNQEGUXBCL-UHFFFAOYSA-L iron(2+);pyridine-3-carboxamide;dichloride Chemical compound [Cl-].[Cl-].[Fe+2].NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 UTELBNQEGUXBCL-UHFFFAOYSA-L 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/40—Fermented products; Products treated with microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/155—Kefiri
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to a dietary supplement for improving or preventing constipation with a lactic acid lactic acid bacteria fermentation product, a pharmaceutical composition for treating or preventing constipation, and a method for producing a lactic acid lactic acid fermentation product of the Lactobacillus to increase the water content and weight of the stool.
- the present invention also relates to a method for producing the lactic acid bacteria fermentation strain and strains used therein.
- Constipation is defined as constipation when medically referred to as less than three times a week or less than 30 g per day. In normal conditions, after 24 hours of food intake is excreted in feces, but people with constipation, even if you see the stool once a few days or every day, the amount of the intestinal dwelling of the ingested food is longer.
- Constipation which is said to be the source of all kinds of illnesses, has no appetite and always has a bloated abdomen, and the toxins of unexcreted stools are absorbed into the blood through the intestine to promote skin aging, headaches, acne, and skin rashes. This appears, if constipation is severe causes of hemorrhoids, such as breakage of the teeth at the time of defecation and escape of dentifrice, and toxins in the shift to colon cancer. In addition, if constipation persists, cholesterol or fat, which should be released into the body, may remain in the body, leading to atherosclerosis or cholelithiasis, and further, high blood pressure and cardiac hypertrophy, which may worsen heart disease. In addition, constipation is an important disease that requires active prevention and treatment because it causes various serious secondary diseases such as stroke, immune deficiency, vision impairment, mental illness (depression).
- Cassia is a perennial herb that belongs to the legumes. Two varieties are known, Cassia obtusifolia L. and Cassia tora L .. The defector is also called super-determination, Longgangnamcha. The first defector is native to Central America, and the other is the tropical Asian, and is grown in China and Korea.
- the shape of the fruit is irregular hexagonal columnar one pointed.
- the outer surface is yellowish brown to blackish brown, 3 to 6 mm long and 2 to 3.5 mm in diameter. Seedlings are firm and lustrous, with a narrow, narrow lined patch on the left and right sides, with a slightly peculiar smell.
- C. obtusifolia has seed alleles and C. tora is small.
- Constipation treatment is caused by senile constipation, senile hypertension, and lack of fluid. It is known to treat dry mouth, abdominal bloating caused by constipation and constipation. .
- Korean Laid-Open Patent Publication No. 1999-0084271 describes that tea bag tea prepared by mixing, or grinding and distributing a defect or cotyledonous leaves and other herbal medicines has an effect on improving constipation
- Korean Laid-Open Patent Publication No. 2003-0062493 discloses First, the leaching extract produced by mixing the extract powder, Cascara sagrada extract powder, etc., which is prepared by extracting, concentrating and spray drying, has excellent palatability and improves constipation symptoms. Grinded, roasted, extracted and concentrated to dry, or mixed with these and other herbal remedies to improve constipation.
- the present inventors have conventionally used for a long time to prove the safety of the lactic acid bacterium, the lactic acid bacterium fermentation product obtained by fermenting the lactic acid bacteria to improve the number of stool, water content of the stool or weight of the stool to improve or treat constipation It has been found that the effect is significantly enhanced to complete the present invention.
- Another object of the present invention is to provide a method for producing a lactic acid bacterium fermentation strain having constipation improvement or preventive activity.
- the present invention provides a dietary supplement for improving or preventing constipation as an active ingredient of Lactobacillus lactic acid bacteria.
- the deficiency extract may be an extract of water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
- the health functional food may be in the form of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jelly or bars.
- the present invention provides a pharmaceutical composition for the treatment or prevention of constipation as an active ingredient of lactic acid bacteria fermentation.
- the deficiency extract may be an extract of water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
- the present invention comprises the steps of preparing the extract; And inoculating and fermenting the lactic acid bacteria in the extract of Lactobacillus.
- the method provides a method for producing Lactobacillus lactobacillus fermented product which increases any one or more of the number of stools, water content of stools, and weight of stools.
- the lactic acid bacteria may be any one or more lactic acid bacteria selected from Lactobacillus genus, Bifidobacterium genus, Leukonostock genus, Pediococcus genus, Enterococcus genus.
- the lactic acid bacteria may be Lactobacillus kefiri MJ90 (Accession No .: KCCM11575P).
- the method for preparing the Lactobacillus lactic acid bacteria fermentation extracting the Lactobacillus or its pulverized product with water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof; And inoculated with Lactobacillus kefiri MJ90 [Accession No .: KCCM11575P] to 1 ⁇ 10 3 to 1 ⁇ 10 6 CFU / mL to the glen extract of the step to ferment for 1 to 7 days at 30 to 45 ° C. It may comprise;
- the extracting may be performed by mixing 10 to 50 parts by weight of water with respect to 1 part by weight of the clarifier pulverizer, and then extracting it for 0.5 to 24 hours while standing or stirring.
- the extracting may be performed by mixing 5 to 30 parts by weight of an aqueous ethanol solution of 20 to 80% by weight based on 1 part by weight of the clarifier or its pulverized product, and extracting the mixture for 0.5 to 24 hours, followed by drying the extract to remove ethanol.
- the lactic acid bacteria nutrient source may be added to the extract of the fermenter in the fermentation step.
- the present invention provides Lactobacillus kefiri MJ90 (Accession No .: KCCM11575P), which ferments the deficiency and promotes constipation improvement or preventive activity.
- the present invention provides a method for the treatment or prevention of constipation patients comprising administering to a constipation patient an effective amount of a deficiency lactobacillus fermentation product.
- Lactic acid bacteria fermented product of the present invention is effective for long-term use of sennoside, or bisacodeyl and docucetate sodium, which is a high-safety and less likely to have side effects as a herbal medicine, and is used for the treatment of irritable constipation forbidden in health functional foods due to side effects. It has the effect of increasing any one or more of the number of sides, the water content of the sides and the weight of the stool equivalent to the commercialized Dulcolax S as a component, and can be used as a pharmaceutical composition for treating or preventing constipation or as a dietary supplement for improving or preventing constipation. Can be.
- the Lactobacillus kefiri MJ90 strain of the present invention is advantageous for the production of Lactobacillus lactic acid bacteria fermented product enhanced constipation treatment, improvement or preventive activity.
- Figure 1 is a graph confirming the progress of lactic acid bacteria fermentation through the change in pH measured at 36 and 72 hours of fermentation when fermented to different fermentation bacteria in different solvents in Experimental Example 1,
- Figure 1b is an extract of Preparation Example 2
- Figure 1c is a fermentation of the dilution of Preparation Example 3, respectively.
- Figure 2 is a graph showing the number of sides of each experimental group in C. of Experimental Example 2.
- Figure 4 is a graph showing the number of sides of each experimental group in C. of Experimental Example 3.
- FIG. 7 is a graph showing the Carmine moving distance of FIG.
- FIG. 8a shows the HPLC-IT / TOP MS pattern of the clarifier ethanol aqueous solution extract of Preparation Example 2 in Experimental Example 4
- FIG. 8b shows the HPLC-IT / TOP MS pattern of the clarifier lactobacillus fermentation of Preparation Example 4 in Experimental Example 4. It is shown.
- FIG. 9 is a schematic diagram of Lactobacillus kefiri MJ90 strain isolated and identified in Experimental Example 9.
- FIG. 9 is a schematic diagram of Lactobacillus kefiri MJ90 strain isolated and identified in Experimental Example 9.
- the present invention relates to a dietary supplement for improving or preventing constipation using lactic acid lactic acid bacteria fermented product as an active ingredient
- the present invention also relates to a pharmaceutical composition for treating or preventing constipation using lactic acid bacteria fermented product as an active ingredient.
- the present invention comprises the steps of preparing the extract extract; And inoculating and fermenting the lactic acid bacteria with the Lactobacillus extract; any one or more of the number of sides, the water content of the sides, and the weight of the sides It relates to a method for producing a lactic acid bacterium fermentation compound to increase.
- the defector is Cassia obtusifolia L. or Cassia tora L., and is preferably Cassia tora L. grown in Korea.
- the extract includes not only the crude extract obtained by treating the extraction solvent with the extraction raw material, but also the processed product of the crude extract.
- the Cassia extract can be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
- the extract also includes a fraction further fractionated the crude extract.
- the lactic acid bacteria for producing the lactic acid lactic acid bacteria may be any one or more lactic acid bacteria selected from Lactobacillus genus, Bifidobacterium genus, Leukonostock genus, Pediococcus genus, Enterococcus genus.
- the lactic acid bacteria may be Lactobacillus paracasei, Lactobacillus kepyri, Lactobacillus ashdophyllus, Bifidobacterium longgum, Bifidobacterium brevis, Leukonostock mesenteroides, Pediococcus pentosase Usus, Enterococcus pecalis.
- Lactobacillus lactic acid bacteria are suitable, more preferably Lactobacillus kepiri or Lactobacillus ashdophyllus , most preferably Lactobacillus kefiri MJ90, which is newly identified and identified by the present inventors.
- the method for preparing the Lactobacillus lactic acid bacteria fermentation extracting the Lactobacillus or its pulverized product with water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof; And inoculating lactic acid bacteria to 1 ⁇ 10 3 to 1 ⁇ 10 6 CFU / ml in the extractor of the above-mentioned step, and fermenting at 30 to 45 ° C. for 1 to 7 days.
- Silver may be obtained by inoculating fermentation with lactic acid bacteria in the extract of the deficiency.
- the components of the Clarifier may be extracted from a diluent mixed by diluting 10 to 50 parts by weight of cold water or room temperature water with respect to 1 part by weight of the Clarifier powder.
- the component of the deficiency may be eluted from the defect in the process of fermentation by lactic acid bacteria. Therefore, in the present invention, the deficiency extract includes a diluted solution of the deficiency powder diluted in water in a broad sense.
- the constipation improvement, treatment or prevention effect of lactic acid bacteria fermented lactic acid bacteria fermented with lactic acid bacteria is somewhat lower, but not lactic acid bacteria fermentation It was confirmed that the effect was significantly increased compared to the extract of the missing name.
- hot water extraction may be used to improve extraction efficiency.
- 10 to 50 parts by weight of water at 80 to 105 ⁇ ⁇ , preferably 90 to 100 ⁇ ⁇ is mixed with respect to 1 part by weight of the clarifier or its pulverized product, followed by standing or stirring for 0.5 to 24 hours, preferably 1 Can be extracted for 6 hours.
- the solvent of the extraction step may be used for 0.5 to 24 hours by mixing 5 to 30 parts by weight of an alcohol having 1 to 4 carbon atoms or an aqueous solution of the alcohol with respect to 1 part by weight of the deficiency or its pulverized product.
- an aqueous alcohol solution such as ethanol, methanol, isopropanol, preferably 20 to 80% by weight of an aqueous alcohol solution, more preferably 50 to 70% by weight of an aqueous alcohol solution.
- the alcohol extract of the alcohol extract is first vaporized before inoculating the lactic acid bacteria, and then concentrated and dried to reduce the alcohol content or alcohol extract, and then used in water.
- lactic acid bacteria nutrients such as protein source, carbohydrate source, vitamin or mineral may be further mixed.
- a starter obtained by mixing or propagating the lactic acid bacteria nutrient source to the lactic acid bacteria before the inoculation of the lactic acid bacteria to the Lactobacillus extract can be used as lactic acid bacteria.
- the lactic acid bacteria nutrient source may use a commercially available medium, or add only necessary nutrient sources individually.
- the deficiency extract, or a mixture of the deficiency extract and lactic acid bacteria nutrient source may be heat sterilized before inoculating the lactic acid bacteria.
- the content of the solid content of the Pulverized extract does not need to be particularly limited, but if there is no other concentration process after extraction, it is 1 to 15% by weight, and may be used immediately, may be used in concentration, or may be diluted and used after concentration or drying.
- Fermentation using the Lactobacillus kefiri MJ90 strain of the present invention, or after the fermentation may be additionally added to supplement the lactic acid bacteria for intestinal action for constipation improvement or prevention.
- the lactic acid bacteria may be any one or more lactic acid bacteria selected from Lactobacillus genus, Bifidobacterium genus, Leukonostock genus, Pediococcus genus, Enterococcus genus.
- the conditions of the step of fermentation are the same as general lactic acid bacteria fermentation, there is no need to specifically limit, it may be carried out at 25 to 40 °C 24 to 96 hours.
- the lactic acid lactic acid bacteria fermentation may be a fermentation product containing the lactic acid bacteria cells, may be a fermentation product from which the lactic acid bacteria cells are removed.
- the fermentation product from which the lactic acid bacteria cells have been removed may be sterilized by the fermentation product to include the dead cells, and may be a filtrate or a centrifugal supernatant from which the cells are removed by filtration or centrifugation.
- the improvement, treatment or prevention effect of the constipation of the present invention is a novel activity having the effect of bioconversion of the components contained in the extract of Lactobacillus to the components that are easy to use in vivo while the lactic acid bacteria are proliferating, or have the effect of improving, treating or preventing constipation It is expected that the ingredients are produced, which is significantly higher than the effect that can be obtained by the addition of simple lactic acid bacteria themselves.
- the lactic acid lactic acid bacteria fermentation may be used as a liquid fermentation itself, it may be dried and powdered.
- Lactobacillus lactic acid bacteria fermented product prepared above can be prepared as a functional ingredient for improving or preventing constipation, or a pharmaceutical composition for treating or preventing constipation.
- the health functional food may be formulated in the form of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jelly or bars in the form of lactic acid bacteria fermentation, or beverages, It is added to food materials such as teas, spices, gums, confectionery, etc. and is manufactured in the form of general foods.In case of ingesting it, it means that it has a specific effect on health. There are no side effects that can occur when taking.
- the health functional food is very useful because it can be consumed on a daily basis.
- the amount of lactic acid lactic acid bacteria fermented product in such a dietary supplement can not be defined uniformly depending on the type of dietary supplement, but may be added within a range that does not impair the original taste of the food. 0.01 to 50% by weight, preferably 0.1 to 20% by weight.
- a health functional food in the form of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jellies or bars 0.1 to 100% by weight, preferably 0.5 to 80% by weight What is necessary is just to add in% range.
- the daily dosage is 0.001-10 g / kg, more preferably 100-1000 mg / kg, even more preferably 200-500 mg / kg, based on the Lactobacillus fermentation strainer.
- the dietary supplement may include not only the lactic acid bacteria fermentation product as an active ingredient, but also components commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents.
- examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol.
- natural flavoring agents such as tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
- synthetic flavoring agents sacharin, aspartame, etc.
- citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further included in addition to the fermented product of the red ginseng of the present invention. have.
- lactic acid lactic acid bacteria fermentation is, for example, 0.001 mg / kg or more, preferably 0.1 mg / kg or more, more preferably 10 mg / kg or more, even more preferably 100 mg / kg or more, even more preferably 250 mg / kg or more.
- Lactobacillus lactobacillus fermentation may be administered between 200 and 500 mg / kg.
- Lactobacillus lactobacillus fermentation product is natural as there is no adverse effect on the human body even when the dose is excessive, the upper limit of the amount of Lactobacillus lactobacillus fermentation contained in the composition of the present invention can be carried out by those skilled in the art selected within an appropriate range.
- the pharmaceutical composition may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coatings, swelling agents, lubricants, lubricants or A flavourant etc. can be used.
- the pharmaceutical composition may be formulated to include one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
- Formulation forms of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions.
- the active ingredient may be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
- Suitable binders include but are not limited to natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like.
- Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- Acceptable pharmaceutical carriers in compositions formulated in liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like.
- One or more components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary.
- Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- the pharmaceutical composition may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, or the like, and preferably, oral administration.
- Suitable dosages of the pharmaceutical compositions vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of the patient, food, time of administration, route of administration, rate of excretion and reaction sensitivity, and are usually skilled The physician can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
- the daily dosage of the pharmaceutical composition is 0.001-10 g / kg, more preferably 100-1000 mg / kg, even more preferably 200-500 mg / kg.
- the pharmaceutical composition may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those skilled in the art. It can be prepared by incorporation into a dose container.
- the formulation may be in the form of a solution, suspension or emulsion in an oil or an aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer.
- the defector crushed domestically produced Cassia tora L. purchased from Chonnam Herbal Agricultural Cooperative (Hwasun-gun) and uniformly crushed with a grinder after washing. Clarifier powder with an average particle size of 300 ⁇ m was prepared and used while refrigerated.
- the distilled water of 10 times the weight of the pulverized glyphs was put in a reflux extractor, extracted twice for 3 hours at 100 ° C., cooled, filtered and concentrated under reduced pressure. Yield was 2.2%.
- the clarifier water diluent was prepared by mixing water so that the pulverized clarifier of Preparation Example 1 became 7% by weight.
- Sterilizer extract obtained by diluting the extractor extract powder of Preparation Example 1 or 2 to 5% by weight in distilled water , or sterilizing water dilution solution of Preparation Example 3 at 121 ⁇ °C, 1.5 atm, for 15 minutes, and then the lactic acid bacteria of Table 1 After activating by culturing at 37 x °C for 24 hours using MRS broth and GAM broth, lactic acid bacteria were inoculated with 5% by weight (1 x 10 7 CFU / ml) of the extract, respectively, at 72 °C for 72 hours. In the meantime, the culture obtained by incubating with stirring at 150 rpm was obtained.
- yeast 5% by weight (1 ⁇ 10 7 CFU / ml) of the yeast culture in which Saccharomyces cerevisiae was activated in advance was inoculated into the extract of Cultivator of Preparation Example 2 (5% by weight of solid content), and then 72 at 30 ° C. For hours, a culture obtained by incubating with stirring at 150 rpm was obtained.
- the culture broth was centrifuged at 6,000 rpm for 15 minutes at 4 ° C to concentrate and lyophilize the supernatant from which the cells were removed, thereby preparing a fermentor fermentate powder.
- the number of viable cells is 1 ml of the sample in 9 ml of sterile physiological saline and mixed well. After diluting stepwise, 0.1 ml is taken and smeared in Lactobacillus genus, Pediococcus genus in MRS agar, and Bifidobacterium genus contains 5% horse blood. Smear the agar and store it in anaerobic condition using anaerobic jar (BBL Gas Pak Anaerobic System) as much as possible incubated at 37 °C for 24-48 hours, and measure the number of colonies generated. Sacchromyces is spread on YM agar and 25 °C. After 48 hours of incubation, the number of colonies produced was measured, and the colony per culture was calculated by multiplying the average number of colonies by the dilution factor.
- Figure 1a is an extract of Preparation Example 1
- Figure 1b is an extract of Preparation Example 2
- Figure 1c is a fermentation of the dilution of Preparation Example 3, respectively.
- the initial pH was 6.4, decreasing from 5.2 to 5.8 at 36 hours and from 4.9 to 5.5 at 72 hours.
- Lactobacillus kefiri MJ90 (L1) and Lactobacillus paracasei (L2) were Lactobacillus acidophillus 128 (L3) , Lactobacillus plantarum 144 (L4), Bifidiobacterium longum (B1) , and Pediococcus pentosaceus (P1) Decreased in width.
- the pH of Sacchromyces cerevisiae (S1) in the dilution of the extract of Preparation Example 1 and Preparation Example 3 was reduced to about the middle of L2 and L3, the pH of the extract of Preparation Example 2 was reduced to a level similar to L3.
- lactic acid bacteria were inoculated into the Lactobacillus extract with a solid content of 6% by weight, 1% by weight, respectively, and fermented at 37 ° C. for 24 hours. After fermentation at °C for 24 hours, the number of viable cells was measured and the results are shown in Table 2.
- the number of viable cells of culture medium prepared using Lactobacillus kefiri MJ90 (L1) strain was three times higher than that of culture medium prepared using Lactobacillus paracasei (L2) strain, and the culture medium prepared using Sacchromyces cerevisiae (S1) strain. 5 times more than the viable count was confirmed.
- the number of viable cells of cultures prepared using Lactobacillus acidophillus 128 (L3) strain and Lactobacillus plantarum 144 (L4) strain was 1/10 of L1 strain, and Bifidiobacterium longum (B1) strain and Pediococcus pentosaceus (P1) strain were used.
- the number of viable cells of the culture solution prepared was 1/100 level of the L1 strain.
- Lactobacillus kefiri MJ90 (L1) strain and Lactobacillus paracasei (L2) strain, and Sacchromyces cerevisiae (S1) strain which are excellent lactic acid bacteria with excellent fermentation characteristics in terms of decreasing pH and increasing number of viable cells, were selected, and comparatively inferior in fermentation characteristics.
- Lactobacillus acidophillus 128 (L3) strains and Bifidiobacterium longum (B1) strains were selected as a group, and animal experiments confirmed that the improvement or prevention of constipation was improved compared to the extracts of the tuber.
- mice were purchased from SD (Sprague Dawley) rats 4 weeks old male was used in Damul Science (Daejeon), and were bred at 20 ⁇ 2 ° C., 55 ⁇ 5% humidity, and 12 hours light and dark conditions. Experimental animals were purified for 1 week after purchase, and then placed 5 animals in each group to set the experimental group as shown in Table 3.
- the 2-200 experimental group administered 200 mg / kg of the ethanol aqueous solution extract of Preparation Example 2 showed almost no significant increase in the number of sides, and 2-L1-200 administered 200 mg / kg in the same manner as the 2-200 experimental group.
- the 2-L2-200 experimental group showed the effect of increasing the number of sides equivalent to sennoside (CON1).
- the 2-500 experimental group to which 500 mg / kg of the ethanol aqueous solution extract of Preparation Example 2 was administered did not show a significant increase in the number of feces.
- the number of sides also increased significantly in the 2-L3-500 and 2-B1-500 experimental groups, which did not show a significant increase in the number.
- 2-S1-500 experimental group did not increase the number of stools even at 500 mg / kg administration.
- the number of stools was increased by the fermentation products of the Lactobacillus kefiri MJ90 (L1) strain and Lactobacillus paracasei (L2) strain, which had the effect of increasing the number of senosides (CON1) equal to or greater than Dulcolax S (CON2).
- the fermented products of Lactobacillus acidophillus 128 (L3) strain and Bifidiobacterium longum (B1) strain showed an effect of increasing the number of stools only in the 500 mg / kg administration group, and the strain of yeast Sacchromyces cerevisiae (S1) increased the number of stools even after fermentation. There was no effect.
- Lactobacillus kefiri MJ90 (L1) strain showed the same number of stools as the normal control group (NOR) in the 500 mg / kg administration group, the most effective in increasing the number of stools.
- the 2-200 experimental group administered 200 mg / kg of the ethanol aqueous solution extract of Preparation Example 2 was weaker than sennoside (CON1), but significantly increased the weight of the stool than the negative control group (LOP).
- 2-L1-200, 2-L2-200 experimental group administered 200 mg / kg in the same manner as the 2-200 experimental group showed sennoside (CON1) and the like and superior to Dulcolax S (CON2) showed an increase in the weight of the side.
- the 2-500 experimental group administered 500 mg / kg of the ethanol aqueous solution extract of Preparation Example 2 showed the weight of the stool similar to that of the 2-200 test group. Although the effect was not obvious, the weight of the stool was significantly increased in the 2-L3-500 and 2-B1-500 experimental groups, which did not show a significant increase in the stool weight in the 200 mg / kg administration group. However, 2-S1-500 experimental group did not increase the weight of stool even at 500 mg / kg administration.
- the weight increase effect of the stool was Lactobacillus kefiri MJ90 (L1) strain was superior to sennoside (CON1), the fermentation product by Lactobacillus paracasei (L2) strains sennoside (CON1) and The weight effect of the stool equivalent to or more than Dulcolax (CON2), and fermented by Lactobacillus acidophillus 128 (L3) strain and Bifidiobacterium longum (B1) strains than sennoside (CON1) and Dulcolaxes (CON2) Although low, only 500 mg / kg administration group showed an increase in the weight of the stool, yeast Sacchromyces cerevisiae (S1) strain was not effective in increasing the weight of the stool even if fermented.
- Experimental animals were prepared in the same manner as in Experimental Example 2, and experimental animals were purified for 1 week after purchase, and then 5 animals were placed in each group to set experimental groups as shown in Table 4.
- 1-L1-100 and 1-L1-200 were administered fermentation products of the Cassiae water extract, 3-L1-100 and 3-L1-200 were administered fermentations of the Cassiae water diluent, 2-L1 -200 (P) is intended to confirm constipation treatment effect after inducing constipation by pretreatment with loperamide.
- each experimental group was orally administered each positive control drug or the fermentation product of Preparation Example 4 for 5 days prior to the administration of loperamide.
- 2-L1-200 (P) was administered subcutaneously by loperamide for 5 days in the same manner as the negative control (LOP) to induce constipation, and then fermented L1 strain of the same extract of Preparation Example 2 as 2-L1-200 ( Preparation Example 4 After oral administration of 200 mg / kg for 5 days, the experimental animals were sacrificed the day after the last fermentation.
- LOP negative control
- 2-L1-200 (P) was removed on the 4th day from the start of fermentation and the remaining 4 days from the start of loperamide administration. The weight is measured.
- both the 1-L1-200 and 3-L1-200 experimental groups administered the same 200 mg / kg significantly increased the number of sides
- the 3-L1-100 experimental group significantly increased the number of stools even after the administration of 100 mg / kg, and showed an effect equivalent to that of Dulcolax S (CON2).
- the 2-L1-200 (P) experimental group administered L1 strain fermentation product of the ethanol aqueous solution extract of Preparation Example 2 after inducing constipation had 26.2 ⁇ 3.1 sides, which was significantly higher than the negative control (LOP). Increased again.
- the weight of the stool was significantly increased in both the 1-L1-200 and 3-L1-200 experimental groups administered the same 200 mg / kg.
- the 1-L1-100 and 3-L1-100 experimental groups administered 100 mg / kg significantly increased the weight of the stool, showing an effect equivalent to Dulcolax (CON2).
- the 2-L1-200 (P) experimental group had a stool weight of 3.18 ⁇ 0.28, which was significantly increased compared to the negative control (LOP).
- Carmine pigment intestinal migration distance was administered orally administered 3mL or 6 days carmine pigment in physiological saline at a concentration of 1.5% (w / v), 20 minutes after oral administration,
- the large intestine is ligated and extracted from both parts after the cecum to the rectum, and the photograph after washing the organs with PBS is shown in FIG. 6, and the measured distance of the Carmine pigment shown in FIG. 6 is shown in FIG. 7. It was.
- the intestinal migration distance of the Carmine pigment was reduced to 6.6 ⁇ 0.75 cm in the loperamide-administered negative control (LOP), compared to the normal control (NOR) of 13.4 ⁇ 0.94 cm, confirming the induction of constipation by loperamide and senno
- the side (CON1) and Dulcolax S (CON2) significantly increased the long travel distance compared to the negative control (LOP).
- the 1-200 test group showed no significant difference from the negative control group (LOP) in the intestinal travel distance, but the 2-200 test group significantly increased the intestinal travel distance compared to the negative control group (LOP).
- the 1-L1-100 and 3-L1-100 experimental groups showed similar intestinal travel distances as the 2-200 experimental group, even when administered in 1/2 the 2-200 experimental group, and the same amount as the 1-200 and 2-200 experimental groups. It was confirmed that the administered 1-L1-200 and 3-L1-200 experimental group significantly increased intestinal travel distance compared to the 2-200 experimental group.
- the 1-L1-200 and 3-L1-200 experimental groups showed intestinal travel distances equal to or greater than those of the positive controls, Senosides and Dulcolax S.
- the 3-L1-200 experimental groups were equivalent to normal controls (NOR). The distance traveled.
- the pattern of the clarifier ethanol aqueous solution extract of Preparation Example 2 is shown in Figure 6a
- the pattern of the clarifier lactic acid bacteria fermentation of Preparation Example 3 is shown in Figure 6b.
- Lactobacillus kefiri MJ90 strain which was the most excellent in the preparation of fermented fermented product with excellent constipation improvement or preventive activity, will be described.
- One piece of Vietnamese mushroom was repeated several times with sterile water for surface cleaning.
- One piece of prepared Vietnamese mushroom was shaken in MRS liquid medium at 37 to 150 rpm for 24 hours, and then diluted three times with sterile water in MRS flat medium containing 1% CaCO 3 .
- Erasmus culture samples diluted 1 ⁇ 10 3 fold were plated after 100 L aliquots in MRS solid medium. Smeared medium was incubated for 36 to 48 hours in a thermo-hygrostat. And morphologically different among the cultured colonies were selected and plated in MRS agar and cultured by pure separation.
- Lactobacillus kefiri MJ90 strain isolated for sequencing was incubated in Lactobacilli MRS broth, 1.5 mL of the culture solution was centrifuged and washed with 0.8% sterile saline solution.
- chromosomal DNA was extracted using genomic DNA kit and used as template DNA for PCR, and 9F (5'-GAG TTT GAT CCT GGC TCA G-3 ') and 1412R (5) were used for amplification of bacterial 16s rRNA.
- 9F 5'-GAG TTT GAT CCT GGC TCA G-3 '
- 1412R (5) were used for amplification of bacterial 16s rRNA.
- '-ACG GCT ACC TTG TTA CGA CTT-3') primers were used.
- PCR product was confirmed by amplification by electrophoresis and purified using a QIAquick PCR purification kit (QIAGEN, Hilden, Germany). Nucleotide sequence ABI PRISM Big Dye TM Terminator Cycle Sequencing Kits (Applied Biosystems, USA) and ABI PRISM 3730xl Analyzer (AppliedBiosystems) Geno Tech Co. using (Daejeon, Korea). Blast search was performed in NCBI using the provided sequencing, and the phylogeny was examined using the MEGA 5.0 program, shown in FIG. 9, and the strain was identified as Lactobacillus kepyri.
- the 16s rRNA sequence of the Lactobacillus kefiri MJ90 is shown in SEQ ID NO: 1, and the Lactobacillus kefiri MJ90 strain was deposited on October 1, 2014 at the Korea Microorganism Conservation Center, KCCM11575P. You have been assigned an accession number.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pediatric Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
구분 | 균주명 | 입수경로 | 사용배지 |
L1 | Lactobacillus kefiri MJ90 | 티벳버섯에서 분리 | MRS |
L2 | Lactobacillus paracasei | 2년숙성 김치에서분리 | MRS |
L3 | Lactobacillus acidophillus 128 | 한국식품연구원 | MRS |
L4 | Lactobacillus plantarum 144 | 한국식품연구원 | MRS |
B1 | Bifidobacterium longum | 한국식품연구원 | RCM / GAM |
P1 | Pediococcus pentosaceus | 한국식품연구원 | MRS |
S1 | Sacchromyces cerevisiae | 상용효모 | YM |
구분 | 생균수(CFU/ml) | |||
발효 전 | 발효 후 (제조예1) | 발효 후 (제조예2) | 발효 후 (제조예3) | |
L1 | 5.0×105 | 7.2×108 | 6.9×108 | 3.3×108 |
L2 | 5.0×105 | 2.6×108 | 2.2×108 | 1.0×108 |
L3 | 5.0×105 | 8.2×107 | 8.1×107 | 4.3×107 |
L4 | 5.0×105 | 5.4×107 | 6.3×107 | 3.2×107 |
B1 | 5.0×105 | 8.8×106 | 1.2×107 | 3.2×106 |
P1 | 5.0×105 | 7.5×106 | 8.1×106 | 1.2×106 |
S1 | 5.0×105 | 1.5×108 | 1.2×108 | 8.6×107 |
구분 | 실험군 |
NOR | 일반 사료 섭취하는 정상 대조군 |
LOP | 변비유발을 위해 로페라미드를 5일동안 4 mg/kg 피하투여한 음성 대조군 |
CON1 | 센노사이드 50 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여한 양성 대조군 |
CON2 | 둘코락스에스 36.25 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여한 양성 대조군 |
2-200 | 제조예2의 결명자물추출물 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L1-100 | 제조예2 추출물의 L1균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L1-200 | 제조예2 추출물의 L1균주 발효물(제조예4) 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L1-500 | 제조예2 추출물의 L1균주 발효물(제조예4) 500 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L2-100 | 제조예2 추출물의 L2균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L2-200 | 제조예2 추출물의 L2균주 발효물(제조예4) 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L2-500 | 제조예2 추출물의 L2균주 발효물(제조예4) 500 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L3-100 | 제조예2 추출물의 L3균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L3-200 | 제조예2 추출물의 L3균주 발효물(제조예4) 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L3-500 | 제조예2 추출물의 L3균주 발효물(제조예4) 500 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-B1-100 | 제조예2 추출물의 B1균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-B1-200 | 제조예2 추출물의 B1균주 발효물(제조예4) 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-B1-500 | 제조예2 추출물의 B1균주 발효물(제조예4) 500 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-S1-100 | 제조예2 추출물의 S1균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-S1-200 | 제조예2 추출물의 S1균주 발효물(제조예4) 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-S1-500 | 제조예2 추출물의 S1균주 발효물(제조예4) 500 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
구분 | 실험군 |
NOR | 일반 사료 섭취하는 정상 대조군 |
LOP | 변비유발을 위해 로페라미드를 5일동안 4 mg/kg 피하투여한 음성 대조군 |
CON1 | 센노사이드 50 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여한 양성 대조군 |
CON2 | 둘코락스에스 36.25 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여한 양성 대조군 |
1-200 | 제조예1의 결명자물추출물 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
1-L1-100 | 제조예1 추출물의 L1균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
1-L1-200 | 제조예1 추출물의 L1균주 발효물(제조예4) 200 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
3-L1-100 | 제조예3 희석액의 L1균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
3-L1-200 | 제조예3 희석액의 L1균주 발효물(제조예4) 100 mg/kg 1주일 경구투여후, 로페라미드 5일동안 4 mg/kg 피하투여 |
2-L1-200(P) | 로페라미드를 5일동안 4 mg/kg 피하투여한 후, 제조예2 추출물의 L1균주 발효물(제조예4) 200 mg/kg 1주일 경구투여 |
Claims (15)
- 결명자 유산균 발효물을 유효성분으로 하는 변비 개선 또는 예방용 건강기능식품.
- 제1항에 있어서, 상기 결명자 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물인 것을 특징으로 하는 변비 개선 또는 예방용 건강기능식품.
- 제2항에 있어서, 상기 건강기능식품은 캡슐, 정제, 분말, 과립, 액상, 환, 편상, 페이스트상, 시럽, 겔, 젤리 또는 바(bar) 형태의 제제인 것을 특징으로 하는 변비 개선 또는 예방용 건강기능식품.
- 결명자 유산균 발효물을 유효성분으로 하는 변비 치료 또는 예방용 약학 조성물.
- 제4항에 있어서, 상기 결명자 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물인 것을 특징으로 하는 변비 치료 또는 예방용 약학 조성물.
- 결명자 추출물을 제조하는 단계; 및 상기 결명자 추출물에 유산균을 접종하여 발효시키는 단계;를 포함하는 변의 개수, 변의 수분 함량 및 변의 중량 중에서 어느 하나 이상을 증가시키는 결명자 유산균 발효물의 제조방법.
- 제6항에 있어서, 상기 유산균은 락토바실러스속, 비피도박테리움속, 류코노스톡속, 페디오코커스속, 엔테로코커스속 유산균 중에서 선택되는 어느 하나 이상의 유산균인 것을 특징으로 하는 결명자 유산균 발효물의 제조방법.
- 제7항에 있어서, 상기 유산균은 락토바실러스 케피리 또는 락토바실러스 애시도필러스인 것을 특징으로 하는 결명자 유산균 발효물의 제조방법.
- 제8항에 있어서, 상기 락토바실러스 케피리는 락토바실러스 케피리(Lactobacillus kefiri) MJ90[기탁번호: KCCM11575P]인 것을 특징으로 하는 결명자 유산균 발효물의 제조방법.
- 제6항에 있어서, 결명자 또는 그 분쇄물을 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매로 추출하는 단계; 및 상기 단계의 결명자 추출물에 유산균을 1×103 내지 1×106 CFU/㎖가 되도록 접종하여 30 내지 45 ℃에서 1 내지 7 일 동안 발효시키는 단계;를 포함하는 결명자 유산균 발효물의 제조방법.
- 제10항에 있어서, 상기 추출하는 단계는 결명자 분쇄물 1 중량부에 대하여 물 10 내지 50 중량부를 혼합한 후 정치 또는 교반하면서 0.5 내지 24 시간 추출하는 것을 특징으로 하는 결명자 유산균 발효물의 제조방법.
- 제10항에 있어서, 상기 추출하는 단계는 결명자 또는 그 분쇄물 1 중량부에 대하여 20 내지 80 중량%의 에탄올 수용액 5 내지 30 중량부 혼합하여 0.5 내지 24 시간 추출한 후, 상기 추출액을 건조하여 에탄올을 제거하는 것을 특징으로 하는 결명자 유산균 발효물의 제조방법.
- 제10항에 있어서, 상기 발효시키는 단계의 결명자 추출물에 유산균 영양원을 더 첨가하는 것을 특징으로 하는 결명자 유산균 발효물의 제조방법.
- 결명자를 발효시켜 변비 개선 또는 예방 활성을 증진시키는 락토바실러스 케피리(Lactobacillus kefiri) MJ90[기탁번호: KCCM11575P].
- 변비 환자에게 유효량의 결명자 유산균 발효물을 투여하는 것을 포함하는 변비 환자의 치료 또는 예방을 위한 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016573990A JP6458059B2 (ja) | 2014-11-04 | 2015-10-27 | 決明子乳酸菌発酵物を有効成分とする便秘改善、治療又は予防用組成物及びその製造方法 |
US15/318,246 US20170252392A1 (en) | 2014-11-04 | 2015-10-27 | Composition for improvement, treatment or prevention of constipation comprising cassia seed lactic acid bacteria fermented product as effective ingredient, and method for preparing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0151888 | 2014-11-04 | ||
KR1020140151888A KR101689192B1 (ko) | 2014-11-04 | 2014-11-04 | 결명자를 발효시켜 변비 개선 또는 예방 활성을 증진시키는 락토바실러스 케피리 균주 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016072655A1 true WO2016072655A1 (ko) | 2016-05-12 |
Family
ID=55909336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/011359 WO2016072655A1 (ko) | 2014-11-04 | 2015-10-27 | 결명자 유산균 발효물을 유효성분으로 하는 변비 개선, 치료 또는 예방용 조성물 및 그 제조방법 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170252392A1 (ko) |
JP (1) | JP6458059B2 (ko) |
KR (1) | KR101689192B1 (ko) |
WO (1) | WO2016072655A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019094313A (ja) * | 2017-11-28 | 2019-06-20 | ビオフェルミン製薬株式会社 | 腹部膨満感改善用組成物及び腹部膨満感改善作用を有する物質又は組成物をスクリーニングする方法 |
KR101895755B1 (ko) * | 2018-05-04 | 2018-09-05 | 한국식품연구원 | 김치유산균주로 구성된 발효 커피 베이스 조성물 및 이를 이용한 발효 커피의 제조방법 |
KR101896275B1 (ko) | 2018-07-30 | 2018-09-07 | (주)지에프씨생명과학 | 락토바실러스 케피리 kr-12 균주 및 이를 이용하여 제조된 발효물 |
CN112544920A (zh) * | 2020-12-03 | 2021-03-26 | 山东腾贵医药有限公司 | 一种改善便秘的组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030096615A (ko) * | 2002-06-17 | 2003-12-31 | 방성모 | 변비개선효과가 우수한 기능성 식품의 조성물 및 그제조방법 |
KR100512322B1 (ko) * | 2004-07-09 | 2005-09-02 | 김양문 | 변비에 개선 효과를 갖는 식물 복발효 효소액 및 이를사용한 기능성 음료 |
JP2009232702A (ja) * | 2008-03-26 | 2009-10-15 | Fisu:Kk | 新規乳酸菌株及びその利用 |
KR20110036036A (ko) * | 2008-06-10 | 2011-04-06 | 가부시키가이샤 피스 | 신규 유발효물 및 그의 이용 |
US20110159148A1 (en) * | 2007-12-06 | 2011-06-30 | Hendrikus Wegkamp | Increased folate production levels in lactobacillus fermenting melon juice |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002265343A (ja) * | 2001-03-07 | 2002-09-18 | Ichimaru Pharcos Co Ltd | 化粧料組成物 |
KR101628962B1 (ko) * | 2014-04-18 | 2016-06-10 | 해남자연농업영농조합법인 | 결명자를 이용한 변비 예방 및 개선제와 그 제조방법 |
-
2014
- 2014-11-04 KR KR1020140151888A patent/KR101689192B1/ko active IP Right Grant
-
2015
- 2015-10-27 WO PCT/KR2015/011359 patent/WO2016072655A1/ko active Application Filing
- 2015-10-27 US US15/318,246 patent/US20170252392A1/en not_active Abandoned
- 2015-10-27 JP JP2016573990A patent/JP6458059B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030096615A (ko) * | 2002-06-17 | 2003-12-31 | 방성모 | 변비개선효과가 우수한 기능성 식품의 조성물 및 그제조방법 |
KR100512322B1 (ko) * | 2004-07-09 | 2005-09-02 | 김양문 | 변비에 개선 효과를 갖는 식물 복발효 효소액 및 이를사용한 기능성 음료 |
US20110159148A1 (en) * | 2007-12-06 | 2011-06-30 | Hendrikus Wegkamp | Increased folate production levels in lactobacillus fermenting melon juice |
JP2009232702A (ja) * | 2008-03-26 | 2009-10-15 | Fisu:Kk | 新規乳酸菌株及びその利用 |
KR20110036036A (ko) * | 2008-06-10 | 2011-04-06 | 가부시키가이샤 피스 | 신규 유발효물 및 그의 이용 |
Also Published As
Publication number | Publication date |
---|---|
JP2017526624A (ja) | 2017-09-14 |
JP6458059B2 (ja) | 2019-01-23 |
KR101689192B1 (ko) | 2016-12-26 |
US20170252392A1 (en) | 2017-09-07 |
KR20160053375A (ko) | 2016-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102134209B1 (ko) | 효소 생산능이 우수한 전통 발효식품 유래 신규 균주 및 이를 이용하여 곡물 발효 효소식품을 제조하는 방법 | |
WO2018062914A1 (ko) | 신규한 락토바실러스 사케이 및 이를 포함하는 조성물 | |
WO2016072655A1 (ko) | 결명자 유산균 발효물을 유효성분으로 하는 변비 개선, 치료 또는 예방용 조성물 및 그 제조방법 | |
WO2011162523A2 (ko) | 쌍화탕 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물 | |
WO2018236011A1 (ko) | 죽순 효소분해물 또는 죽순 발효물을 유효성분으로 포함하는 장기능 저하 예방, 개선 또는 치료용 조성물 | |
WO2020116962A1 (ko) | 작약 추출물의 유산균 발효물을 유효성분으로 포함하는 당뇨병의 예방, 개선 또는 치료용 조성물 | |
KR20170134921A (ko) | 발효 뽕잎, 발효 뽕잎 추출물 및 이의 용도 | |
WO2023055188A1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2010131910A2 (ko) | 발효차를 함유하는 혈액 순환 개선용 조성물 및 이를 포함하는 약제학적 및 건강 식품 조성물 | |
WO2021080297A1 (ko) | 달맞이꽃 추출물을 유효성분으로 포함하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
KR100889300B1 (ko) | 바실러스 서브틸리스 kk71 균주 및 이의 배양액을유효성분으로 함유하는 혈당강하용 조성물 | |
WO2011074765A2 (ko) | 한약재 발효물을 유효성분으로 포함한 비만 또는 고지혈증의 예방 및 치료용 조성물 | |
KR101745597B1 (ko) | 발효 감잎, 발효 감잎 추출물 및 이의 용도 | |
KR102438276B1 (ko) | 괭생이모자반 추출물을 포함하는 항염증 및 항비만 조성물 및 이의 제조방법 | |
KR101510673B1 (ko) | 인삼 사포닌의 장내 세균 대사 억제용 조성물 | |
WO2023058801A1 (ko) | 락토바실러스 애시도필러스 kbl402 또는 kbl409 균주를 포함하는 장 질환 개선, 예방 또는 치료용 조성물 | |
WO2022039514A1 (ko) | 락토바실러스 사케이 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물 | |
KR101600884B1 (ko) | 결명자 유산균 발효물을 유효성분으로 하는 변비 개선, 치료 또는 예방용 조성물 | |
WO2021071159A1 (ko) | 서목태의 효모 발효물을 포함하는 혈당강하, 혈압강하 또는 항산화용 조성물 및 상기 조성물의 제조 방법 | |
KR101808306B1 (ko) | 결명자를 발효시켜 변비의 개선 또는 예방 활성을 증진시키는 락토바실러스 카제이 균주 | |
WO2020004858A1 (ko) | 효모 추출물을 포함하는 당뇨 개선 또는 항산화용 조성물 및 효모 추출물의 제조 방법 | |
WO2024038980A1 (ko) | 락토바실러스 플란타럼 ku15120 균주 또는 이의 용도 | |
KR102577648B1 (ko) | 바실러스 서틸리스 sb051 균주 또는 이를 이용한 콩 발효물을 유효성분으로 포함하는 비만의 예방, 개선 또는 치료용 조성물 | |
WO2023140565A1 (ko) | 유산균을 이용한 알파-글루코사이드 활성 저해능을 가지는 혈당강하용 조성물, 건강기능식품 및 약학적 조성물 | |
WO2024063543A1 (ko) | 락토바실러스 플란타룸 균주 및 한약재를 포함하는 병용 요법을 이용한 암 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15856398 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15318246 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016573990 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15856398 Country of ref document: EP Kind code of ref document: A1 |